Home
Live Updates
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators : vimarsana.com
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American...
Related Keywords
San Diego ,
California ,
United States ,
Germany ,
Munich ,
Bayern ,
American ,
Inflarx Gmb ,
Regina Lutz ,
Camilla Chong ,
Laurie Doyle ,
Jan Medina ,
Katja Arnold ,
Globenewswire Inc ,
Inflarx Pharmaceuticals Inc ,
Inflarx Commitment Program ,
Drug Administration ,
American Thoracic Society ,
International Conference ,
European Medicines Agency ,
Mc Services ,
Thoracic Society ,
Baricitinib Dramatically Improves Mortality ,
Critically Ill ,
Acute Respiratory Failure ,
Chief Medical Officer ,
Fact Sheet ,
Healthcare Providers ,
Safety Information ,
Marketing Authorization Application ,
Medicines Agency ,
vimarsana.com © 2020. All Rights Reserved.